ALIGOS THERAPEUTICS INC (ALGS)
$1.1
Live
Insights on ALIGOS THERAPEUTICS INC
Decreasing Revenue
Revenue is down for the last 3 quarters, 4.10M → 140.0K (in $), with an average decrease of 55.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -18.62M → -22.95M (in $), with an average decrease of 11.2% per quarter
Vs SGEN
In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 47.2%
Performance
- $1.09$1.12$1.10
0.91%
Downside
Day's Volatility :2.68%
Upside
1.79%
- $0.84$2.41$1.10
23.63%
Downside
52 Weeks Volatility :65.14%
Upside
54.36%
Returns
| Period | ALIGOS THERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -23.29% | 0.3% | -6.7% |
6 Months | 12.0% | -8.3% | -6.2% |
1 Year | -13.18% | -4.8% | -6.3% |
3 Years | -92.46% | 23.8% | 26.9% |
Highlights
Market Capitalization | 47.7M |
Book Value | $1.97 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.99 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -611.29% |
Return On Assets TTM | -32.34% |
Return On Equity TTM | -70.18% |
Revenue TTM | 14.1M |
Revenue Per Share TTM | 0.33 |
Quarterly Revenue Growth YOY | 5.8999999999999995% |
Gross Profit TTM | -71.2M |
EBITDA | -83.9M |
Diluted Eps TTM | -1.99 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.82 |
EPS Estimate Next Year | -1.15 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.45 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 263.64%
Technicals Summary
Sell
Neutral
Buy
ALIGOS THERAPEUTICS INC is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 ALIGOS THERAPEUTICS INC | -11.81% | 12.0% | -13.18% | -92.46% | -92.46% |
 Moderna, Inc. | -5.37% | -28.24% | -13.14% | 103.02% | 578.71% |
 Regeneron Pharmaceuticals, Inc. | -10.12% | -3.55% | 9.07% | 20.95% | 140.97% |
 Seagen, Inc. | -2.85% | 59.4% | 42.61% | 21.68% | 240.77% |
 Vertex Pharmaceuticals Incorporated | -4.35% | 4.3% | 22.83% | 15.12% | 110.67% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
ALIGOS THERAPEUTICS INC | NA | NA | NA | -1.82 | -0.7 | -0.32 | 0.0 | 1.97 |
Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.83 | 0.27 | 0.12 | 0.0 | 49.12 |
Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
ALIGOS THERAPEUTICS INC | Buy | $47.7M | -92.46% | NA | 0.0% |
Moderna, Inc. | Buy | $48.1B | 578.71% | 11.22 | 31.77% |
Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 140.97% | 19.72 | 33.81% |
Seagen, Inc. | Hold | $36.3B | 240.77% | NA | -31.55% |
Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 110.67% | 26.53 | 35.4% |
Institutional Holdings
EcoR1 Capital, LLC
9.20%Vivo Capital, LLC
8.26%TANG CAPITAL MANAGEMENT LLC
7.98%Versant Venture Management LLC
5.40%Hillhouse Capital Advisors, Ltd.
5.38%Baker Bros Advisors LP
4.84%
Corporate Announcements
ALIGOS THERAPEUTICS INC Earnings
ALIGOS THERAPEUTICS INC’s price-to-earnings ratio stands at None
Read More
Company Information
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Organization | ALIGOS THERAPEUTICS INC |
Employees | 69 |
CEO | Dr. Lawrence M. Blatt MBA, Ph.D. |
Industry | Health Technology |
Discover More
Presto Automation Inc
$2.96
-17.48%
D-MARKET ELECTRONIC SERVICES
$1.06
+1.92%
Mexico MSCI Capped ETF iShares
$61.11
-0.18%
Global X S&P Catholic Values Developed ex-US ETF
$27.94
-0.54%
IndexIQ ETF Trust - IQ Chaikin U.S. Small Cap ETF
$30.88
-0.19%
DFA Dimensional Internatl High Profitability ETF
$23.94
-0.58%
Precigen Inc
$1.22
+0.0%
EXSCIENTIA PLC
$7.26
-8.79%
ISHARES GEN-IMMUNOLOGY HLTH
$24.13
+0.42%